William Blair & Company
ABBV icon

William Blair & Company’s AbbVie ABBV Stock Holding History

William Blair & Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,100
Closed -$80K – 1357
2017
Q2 		$80K Buy
1,100
+200
+22% +$13.4K ﹤0.01% 1438
2017
Q1 		$59K Buy
900
+200
+29% +$12.6K ﹤0.01% 1324
2016
Q4 		$44K Buy
+700
New +$42.7K ﹤0.01% 1264

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

William Blair & Company's ABBV Position: Q2 2026 in Review

William Blair & Company reduced its AbbVie (ABBV) stake by 3.5% in Q2 2026, selling an estimated $9.95M and leaving 1,287,857 shares worth $324M. The position accounts for 0.84% of the portfolio, ranked #24.

William Blair & Company first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • William Blair & Company held 1,287,857 shares of AbbVie worth $324M as of Q2 2026.
  • William Blair & Company sold 46,252 AbbVie shares in Q2 2026, an estimated $9.95M.
  • AbbVie made up 0.84% of William Blair & Company's portfolio in Q2 2026, its #24 holding.
  • William Blair & Company first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.